Targeted Nano-Based Systems for the Anti-Obesity Agent's Delivery

Area of Science:

• Biomedical Engineering
• Pharmacology
• Nanotechnology

Background:

• Obesity is a chronic global health issue linked to increased mortality and reduced life expectancy.
• Existing anti-obesity drugs often suffer from ineffectiveness or adverse side effects.
• Nanotechnology offers potential solutions to overcome these limitations in obesity treatment.

Purpose of the Study:

• To review how nanocarriers impact the properties and bioactivity of anti-obesity drugs.
• To explore the potential of nanocarrier-based delivery for micro-ribonucleic acids (miRNAs) in obesity treatment.
• To evaluate the synergistic effects of combined drug and gene therapy using nanocarriers for obesity.

Main Methods:

• Review of current literature on nanocarrier applications in anti-obesity drug delivery.
• Analysis of pharmacokinetic and biodistribution profiles of nanocarrier-formulated drugs.
• Investigation into the role of micro-ribonucleic acids (miRNAs) delivered via nanoparticles.

Main Results:

• Nanocarriers can improve the safety of anti-obesity drugs by reducing systemic toxicity and enhancing targeting.
• Encapsulated miRNAs show efficacy in modulating obesity-related metabolic pathways and gene networks.
• Co-delivery of drugs and genes in nanocarriers demonstrates synergistic anti-obesity effects with lower doses and toxicity.

Conclusions:

• Nanocarriers represent a promising platform for developing safer and more effective anti-obesity therapies.
• Targeted delivery and combination therapy using nanocarriers can overcome limitations of conventional treatments.
• Further research into nanocarrier-based interventions holds significant potential for managing obesity and related complications.